Single Ascending Dose Study of PRX002 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.

Inclusion Criteria:

• Healthy subjects
• Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg
• Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
• Male subjects and their partners of childbearing potential must use contraception

Exclusion Criteria:

• Positive test for drug of abuse
• Past or current history of alcohol abuse
• Positive for hepatitis B, hepatitis C or HIV infection